Skip to main content
UCB logo

UCB — Investor Relations & Filings

Ticker · UCB ISIN · BE0003739530 LEI · 2138008J191VLSGY5A09 BR Manufacturing
Open in API
Filings indexed 2,023 across all filing types
Latest filing 2011-03-04 AGM Information
Country BE Belgium
Listing BR UCB

About UCB

https://www.ucb.com/

UCB is a global biopharmaceutical company that focuses on creating solutions for people living with severe diseases, primarily in the fields of neurology and immunology. The company's core activities include the research, development, and commercialization of pharmaceutical and biotechnology products. Guided by a patient-centric and science-driven approach, UCB is committed to innovation and sustainability. Through its UCB Ventures arm, it invests in pioneering technologies and companies with the potential to transform patient care. The company also offers personalized support services to patients and healthcare professionals during their treatment journey with a UCB medicine.

Recent filings

Filing Released Lang Actions
CONVOC AGE1 ENG 2011.pdf
AGM Information Classification · 98% confidence The document explicitly invites shareholders to attend an 'Extraordinary General Meeting' (EGM) on a specific date (Thursday, 31st March 2011) and lists several items on the agenda, which are presented as 'Proposal of resolution'. These resolutions primarily concern amending the articles of association (e.g., director term limits, creating a remuneration committee, adapting to new shareholder rights laws). The text details voting procedures, proxy requirements, and necessary deposits for attendance. This content is characteristic of the preparatory materials or the official notice for a shareholder meeting, specifically focusing on the resolutions to be voted upon, which aligns best with the definition of AGM Information (AGM-R), even though it is an Extraordinary General Meeting, as it deals with the meeting's agenda and proposals.
2011-03-04 English
Convoc AGE1 FR 2011.pdf
AGM Information Classification · 98% confidence The document explicitly calls for shareholders to attend an 'Assemblée Générale Extrardinaire' (Extraordinary General Meeting) on March 31, 2011, and details the agenda items. The agenda focuses entirely on proposed modifications to the company's statutes (bylaws) regarding director terms, establishing a remuneration/nomination committee, and aligning statutes with new shareholder rights laws. This content is the core material presented to shareholders for a vote at a general meeting, which aligns perfectly with the purpose of an Annual General Meeting (AGM) or Extraordinary General Meeting (EGM) material. Since the document is the notice and agenda for the meeting itself, and not just a proxy statement (PSI) or voting results (DVA), the most appropriate classification is AGM-R, as it covers the materials presented at the meeting.
2011-03-04 French
Convoc AGE1 NL 2011.pdf
AGM Information Classification · 98% confidence The document explicitly calls for shareholders to attend an 'Buitengewone Algemene Vergadering' (Extraordinary General Meeting) on March 31, 2011, to deliberate on several agenda points, primarily concerning amendments to the company's articles of association (statutenwijziging) regarding director mandates, the establishment of a remuneration and nomination committee, and compliance with new shareholder rights legislation. This content is the formal notice and agenda for a shareholder meeting, which aligns perfectly with the definition of materials shared during an Annual General Meeting (AGM) or a related special meeting. Although it is an Extraordinary General Meeting (EGM), the closest and most appropriate category covering meeting materials is AGM-R (AGM Information). It is not a DEF 14A (Remuneration Information) because the focus is on statutory changes, not just compensation disclosure, and it is not a DVA (Declaration of Voting Results) as it is the notice *before* the meeting.
2011-03-04 Dutch
FY 2010 results_ENG.pdf
Earnings Release Classification · 98% confidence The document is explicitly titled '# Full-year Report 2010' and contains comprehensive financial performance data for the full year 2010, including revenue, net profit, balance sheet details, cash flow, dividend recommendation, and R&D updates. This level of detail and the explicit mention of 'full year' results strongly indicate it is the company's official annual report. Although it is an announcement dated March 2, 2011, the content provided is the report itself, not just a brief announcement of its publication. The structure and content align best with the definition of an Annual Report (10-K), even if it is presented in a press release format summarizing the 10-K data. Given the comprehensive nature of the financial review, 10-K is the most appropriate classification over a simple Earnings Release (ER) or Report Publication Announcement (RPA). FY 2010
2011-03-02 English
FY 2010 results_FR.pdf
Earnings Release Classification · 98% confidence The document is titled "Résultats financiers 2010" and contains detailed financial figures for the full year 2010, including revenue, EBITDA, net income, balance sheet data, cash flow, dividend recommendations, and forward-looking guidance for 2011. It explicitly states, "UCB a présenté aujourd'hui ses résultats financiers consolidés pour l'année écoulée : 2010 a été une nouvelle année riche en événements." This content structure—comprehensive annual financial review, balance sheet, and management commentary on the full fiscal year—is characteristic of an Annual Report (10-K) or a very detailed Earnings Release/Interim Report. Since it covers the full year and includes balance sheet/cash flow details, it is more comprehensive than a typical Earnings Release (ER) or Interim Report (IR). However, the text is presented as a press release dated March 2, 2011, summarizing the year 2010, which often aligns with the content of an Earnings Release (ER) or a Management Discussion & Analysis (MDA) section that precedes the full 10-K filing. Given the depth of financial detail (including balance sheet and cash flow) but presented as a press release announcing the results, it strongly resembles a comprehensive Earnings Release or the core financial narrative often found in an MDA. Since the definitions prioritize 'ER' for initial announcements of periodical results and '10-K' for the official yearly report, and this document is a detailed summary released early in the following year (March 2011 for FY2010), it fits best as a comprehensive Earnings Release (ER) or potentially a Management Report (MDA) if it were purely narrative. Because it contains the full financial summary, ER is the most appropriate fit among the options for a detailed period-end announcement that isn't the full 10-K filing itself. The length (21,500 chars) suggests it is more than just highlights, leaning towards ER or MDA. Given the focus on 'Résultats financiers' and the forward-looking guidance, ER is selected as the primary classification for a detailed period-end results announcement. FY 2010
2011-03-02 French
2010 annual report - NL.pdf
Annual Report Classification · 100% confidence The document is a comprehensive annual report for UCB, containing a letter to shareholders, financial highlights, strategic overviews, and detailed sections on business performance, R&D, and corporate governance. It is clearly a full annual report rather than a summary or announcement, as evidenced by the extensive page references (e.g., 'Financieel verslag' on page 70, 'Geconsolideerde jaarrekening' on page 80) and the depth of the content provided. FY 2010
2011-03-02 Dutch

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.